J Gastroenterol Hepatol: Dingpronotone Improves Gastric Muscosis Damage and Indigestion Symptoms in Long-Term Nonsteroidal Anti-Inflammatory Drug Users

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the main cause of gastric mucosa lesionsIn China, diprione is often used as a mucous membrane protector, but the literature on its efficacy is limitedThe purpose of this study was to explore the effects of diprionon on long-term use of NSAID-related gastric mucosa lesionsstudy examined 369 patients who took NSAIDs for at least 12 weeksPatients with no gastric duodenal ulcers, endoscopy without Helicobacter pyloriinfectionwere randomly received nSAID plus tipreenone (150mg/day) or only NSAID for 12 weeksThe Lanza score was checked with an endoscopy before and after treatment, and theindigestionsymptoms scoreA total of 158 patients were randomly assigned to the prepreketone group (n s 74) or the control group (n s 84) for a period of 12 weeksFinally, after the treatment of 71 patients in the Tepriketone group and 79 patients in the control group, the Lanza score andindigestionindigestion were significantly lower, while the control group increased (P 0.05)The Lanza score and indigestion symptom score of the diprionone group changed higher than those in the control group (P 0.05)Subgroup analysis, the long-term treatment of low-dose aspirin of Tepriketone group and other nonsteroidal anti-inflammatory drugs in the group of Tepriketone, Lanza score and indigestion symptoms score changes significantly improved (P 0.05) , the results show that for patients with long-term use of nonsteroidal anti-inflammatory drugs without Helicobacter pylori infection or a history of gastric duodenal ulcers, dipronone may be an effective treatment option for gastric mucosa damage and indigestion symptoms